DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Conference
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis

12.12.2021 / 15:00
The issuer is solely...
Quelle: Börse Online RSS Feed